EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites

Asma El-Zailik iD, Jennifer Sager, Yasmin Sánchez-Pearson iD, Sergio Parra iD, Jennifer Moore, Prosenjit Sarkar, Alicia Aylott, Qianwen Wang, Melissa Aldinger, Chad Garner, Erik Mogalian, Andrew Skingsley und 2 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3515 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Asma El-Zailik und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vir Biotechnology, Inc., San Francisco, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Vir Biotechnology, Inc., GSK, Vir Biotechnology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotrovimab is a recombinant human monoclonal antibody for the early treatment of mild‐to‐moderate COVID‐ 19. A phase I, open‐label, randomized, parallel‐group study was conducted to investigate the pharmacokinetics, relative bioavailability, safety, and tolerability of two concentrations of sotrovimab administered intramuscularly at different injection sites in healthy volunteers. The study consisted of three parts (A, B, and C) and the pharmacokinetic results from Part A are reported herein. In Part A, participants were randomized in a 2:2:1:1 ratio to a 500 mg dose of 62.5 mg/mL sotrovimab administered into dorsogluteal muscle, or 100 mg/mL sotrovimab administered into dorsogluteal, anterolateral thigh, or deltoid muscles. Formulation concentration did not impact exposure following dorsogluteal administration; the point estimates (90% confidence interval [CI]) of the geometric mean ratios (GMRs) of area under the curve (AUC) inf and maximum serum concentration ( C max ) for dorsogluteal administration of 100 mg/mL vs. 62.5 mg/mL intramuscular sotrovimab were 0.95 (0.86–1.05) and 1.14 (1.02–1.27), respectively. However, the administration of 100 mg/mL sotrovimab in thigh or deltoid resulted in increased exposure relative to gluteal injections; the point estimates (90% CI) of the GMRs for 100 mg/mL intramuscular sotrovimab administered into thigh or deltoid muscles vs. 100 mg/mL administered dorsogluteally were 1.63 (1.46–1.83) and 1.50 (1.34–1.67) for AUC inf , and 1.82 (1.60–2.08) and 1.49 (1.31–1.69) for C max , respectively. Notably, thigh and deltoid administration also resulted in lower variability in key pharmacokinetic parameters such as AUC, C max , apparent clearance and volume of distribution, and earlier achievement of C max , than dorsogluteal intramuscular administration of sotrovimab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHumansMaleInjections, IntramuscularAdultFemaleHealthy VolunteersYoung AdultArea Under CurveMiddle AgedBiological AvailabilityCOVID-19 Drug TreatmentThigh

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Vir Biotechnology, Inc., San Francisco, California, USA.
  • GSK, Brentford, UK.
  • GSK, Bengaluru, India.
  • GSK, Stevenage, UK.
  • GSK, Cambridge, Massachusetts, USA.

ORCID-Profile: Asma El-Zailik, Yasmin Sánchez-Pearson, Sergio Parra

Förderung

  • Vir Biotechnology, Inc.
  • GSK
  • Vir Biotechnology
  • GlaxoSmithKline Japan

Zitieren

APA

El-Zailik, A., Sager, J., Sánchez-Pearson, Y., Parra, S., Moore, J., Sarkar, P., Aylott, A., Wang, Q., Aldinger, M., Garner, C., Mogalian, E., Skingsley, A., Peppercorn, A., & Reyes, M. (2025). Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3515

Vancouver

El-Zailik A, Sager J, Sánchez-Pearson Y, Parra S, Moore J, Sarkar P, et al. Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3515

BibTeX
@article{ElZailik2025,
  author = {El-Zailik, Asma and Sager, Jennifer and Sánchez-Pearson, Yasmin and Parra, Sergio and Moore, Jennifer and Sarkar, Prosenjit and Aylott, Alicia and Wang, Qianwen and Aldinger, Melissa and Garner, Chad and Mogalian, Erik and Skingsley, Andrew and Peppercorn, Amanda and Reyes, Maribel},
  title = {Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3515}
}
Kostenlos starten →